Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766726 | 0.75 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP2A6RAB9ANPC1 | |
| SCHEMBL13568569 | 0.74 | RAB9A (0.50) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7045457 | 0.71 | MAPT (0.40) | ALDH1A1MAPTRAB9ANPC1AHR | |
| SCHEMBL7042202 | 0.71 | MAPT (0.40) | ALDH1A1MAPTRAB9ANPC1AHR | |
| SCHEMBL30677005 | 0.68 | CYP2A6 (0.44) | ALDH1A1MAPTCYP2A6RAB9ANPC1 | |
| SCHEMBL1309456 | 0.67 | — | — | |
| SCHEMBL7041871 | 0.66 | HPGD (0.44) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12687094 | 0.65 | ALDH1A1 (0.42) | ALDH1A1MAPTCYP2A6 | |
| SCHEMBL12687033 | 0.64 | ALDH1A1 (0.41) | ALDH1A1MAPTCYP2A6 | |
| SCHEMBL9755100 | 0.64 | MAPT (0.71) | ALDH1A1MAPTRAB9ANPC1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346832-B2 | Gold complexes for use in the treatment of cancer | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2016-05-24 | — | — | US | disclosed |
| US-9346832-B2 | Gold complexes for use in the treatment of cancer | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2016-05-24 | — | — | US | disclosed |
| US-9346832-B2 | Gold complexes for use in the treatment of cancer | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2016-05-24 | — | — | US | disclosed |
| US-20130090472-A1 | GOLD COMPLEXES FOR USE IN THE TREATMENT OF CANCER | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090472-A1 | GOLD COMPLEXES FOR USE IN THE TREATMENT OF CANCER | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090472-A1 | GOLD COMPLEXES FOR USE IN THE TREATMENT OF CANCER | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2013-04-11 | — | — | US | disclosed |
| WO-2011158176-A2 | GOLD COMPLEXES | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2011-12-22 | — | — | WO | disclosed |
| US-20030162960-A1 | Colormetric sensor compositions and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-28 | — | — | US | disclosed |
| US-6482949-B1 | Colormetric sensor compositions and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090472-A1 | GOLD COMPLEXES FOR USE IN THE TREATMENT OF CANCER | PYM1, SLC39A11, SLC39A3 | ALDH1A1 2366/4885MAPT 3929/4885CYP2A6 769/4885 |
| US-20030162960-A1 | Colormetric sensor compositions and methods | PAH, NISCH, SPR | ALDH1A1 1798/4885MAPT 2663/4885CYP2A6 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.